Try our beta test site
41 studies found for:    Open Studies | Burkitt's Lymphoma | Phase 1
Show Display Options
Rank Status Study
1 Recruiting The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Condition: B-cell Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CART-19 cells
2 Recruiting CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Burkitt Lymphoma
Interventions: Procedure: Leukapheresis;   Drug: Lymphodepletion with fludarabine;   Drug: Lymphodepletion with cyclophosphamide;   Biological: CD19 CAR T-cells
3 Recruiting Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Biological: gene-modified T cells targeted
4 Recruiting Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
Conditions: Refractory B-cell Acute Lymphoblastic Leukemia;   Relapsed B-cell Acute Lymphoblastic Leukemia
Intervention: Genetic: UCART19
5 Recruiting Dose Escalation Study to Evaluate the Safety, Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed / Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL)
Conditions: Acute Lymphoblastic Leukaemia;   Chronic Lymphocytic Leukaemia
Intervention: Genetic: UCART19
6 Recruiting A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
Conditions: Diffuse Large B-cell Lymphoma;   Follicular Lymphoma;   Burkitt Lymphoma
Intervention: Drug: Alisertib
7 Recruiting A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL
Condition: Relapsed or Refractory Acute Lymphoblastic Leukemia
Intervention: Biological: C-CAR-011
8 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: ADCT-402
9 Recruiting S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
10 Recruiting Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: CART-19
11 Recruiting Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: Cytarabine;   Biological: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
12 Recruiting PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Conditions: Acute Myelogenous Leukemia;   B-cell Acute Lymphoblastic Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Chronic Myeloid Leukemia, Blast Crisis
Intervention: Biological: XmAb14045
13 Not yet recruiting Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
14 Recruiting ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Conditions: Non-hodgkins Lymphoma;   Multiple Myeloma;   B-All
Intervention: Drug: ACP-196 and ACP-319
15 Recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Venetoclax
16 Recruiting Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Drug: Romidepsin
17 Recruiting Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Mediastinal Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Waldenstrom Macroglobulinemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
18 Recruiting Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Lymphoblastic Lymphoma;   Diffuse Large B-cell Lymphoma;   Burkitt Lymphoma/Leukemia
Interventions: Drug: Clofarabine;   Drug: Mitoxantrone
19 Recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Clearing Agent;   Drug: Cytarabine;   Drug: Etoposide;   Radiation: Indium In 111-DOTA-Biotin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Yttrium Y 90-DOTA-Biotin
20 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Conditions: Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom Macroglobulinemia
Intervention: Drug: ADCT-402

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.